Two neutralizing monoclonal antibodies isolated from volunteers vaccinated against the yellow fever virus controlled the viremia and prevented severe disease and death in hamsters and primates.

Gandeeva Therapeutics Inc. has entered into a research collaboration with Moderna Inc. to...

A research team based at MIT and Harvard has engineered a bacterial injection system to precisely deliver proteins to human cells. This work, published online March 29, 2023, in Nature, is important as while more and more molecular therapies are being developed, off-target effects are always a concern and precise targeting of cells and tissues can still be a challenge.

Moderna Inc. and Generation Bio Co. have entered into a strategic collaboration to combine Moderna’s biological and technical expertise...

Charm Therapeutics Ltd. has entered into a strategic discovery collaboration with Bristol Myers Squibb Co. for the identification and optimization of compounds against Bristol Myers Squibb's selected targets.

Talem Therapeutics LLC, an independently...

Switch Therapeutics Inc. has announced its launch following US$52 million of financing. The company was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.

Epic Bio (Epicrispr Biotechnologies Inc.) has presented new data demonstrating the achievement of persistent gene activation using its Gene Expression Modulation System (GEMS) platform.

Two molecules that affected the cell cycle only of acute myeloid leukemia (AML) cells could be used as a clinical strategy against this pathology. Scientists at Memorial Sloan Kettering Cancer Center and Harvard University have discovered that DEG-35 and DEG-77 arrested the cell cycle and promoted cell differentiation and apoptosis in these cells.